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Abstract: Anterior segment dysgenesis (ASD) encompasses a wide spectrum of developmental abnormalities of the anterior ocular segment, including congenital cataract, iris hypoplasia, aniridia,
iridocorneal synechiae, as well as Peters, Axenfeld, and Rieger anomalies. Here, we report a large fivegeneration Caucasian family exhibiting atypical syndromic ASD segregating with a novel truncating
variant of FOXC1. The family history is consistent with highly variable autosomal dominant symptoms including isolated glaucoma, iris hypoplasia, aniridia, cataract, hypothyroidism, and congenital
heart anomalies. Whole-exome sequencing revealed a novel variant [c.313_314insA; p.(Tyr105*)] in
FOXC1 that disrupts the α-helical region of the DNA-binding forkhead box domain. In vitro studies
using a heterologous cell system revealed aberrant cytoplasmic localization of FOXC1 harboring the
Tyr105* variant, likely precluding downstream transcription function. Meta-analysis of the literature
highlighted the intrafamilial variability related to FOXC1 truncating alleles. This study highlights
the clinical variability in ASD and signifies the importance of combining both clinical and molecular
analysis approaches to establish a complete diagnosis.
Keywords: FOXC1; in vitro studies; novel variant; ophthalmic genetics; intrafamilial variability;
anterior segment dysgenesis
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1. Introduction
Anterior segment dysgenesis (ASD) encompasses a wide spectrum of developmental
abnormalities of the anterior ocular segment coupled with increased risk of glaucoma,
Peters anomaly, iris hypoplasia, corectopia, or sclerocornea, which may lead to blindness [1].
Syndromic ASD is caused by specific genes, predominantly transcription factors and
cofactors such as PAX6, PITX2, and FOXC1 [2–8], that are critical for the development of
many tissues, including ocular, neuronal, craniofacial, dental, cardiac, and renal. Clinical
heterogeneity, both phenotypic and genotypic, along with the overlapping of symptoms
associated with anterior segment dysgenesis make the disease classification and clinical
diagnosis challenging. This has been the case despite several attempts to categorize ASD to
aid the diagnosis [9–11].
Forkhead box C1 (FOXC1) belongs to a family of transcription factor genes, and heterozygous variants have been associated with Axenfeld-Rieger syndrome and ASD [12–14].
FOXC1 plays a critical role during early development, specifically for the development of
the anterior segment of the eye, including iris, lens, and cornea. Further, FOXC1 is involved
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in the normal development of the kidney, brain, and heart [15–17]. More than 50 different
variants in FOXC1 have been associated with Axenfeld-Rieger syndrome type 3. Variants
may reduce the amount of functional FOXC1 that is produced or affect the DNA binding
capability of FOXC1, resulting in functional haploinsufficiency, leading to variable ASD in
humans and mice [18,19]. Variable expressivity associated with FOXC1 variants may be
quite broad, with the observation of Peters anomaly, iris hypoplasia, or corectopia among
family members harboring the same causal variant [13]. Here, we describe a novel truncating variant in FOXC1 causing autosomal dominant atypical ASD with highly variable
phenotypic spectrum including variable iris hypoplasia and aniridia in a large Caucasian
family. We also perform an extensive meta-analysis of the literature to explore the range
and frequency of phenotypes related to FOXC1 truncating alleles segregating in families.
2. Materials and Methods
2.1. Clinical Evaluation
This study was conducted under institutional review board-approved protocols in
accordance with the Declaration of Helsinki for the release of clinical information, family
history, blood draw, and skin biopsies. Informed consent was obtained after the explanation
of the study’s risks and benefits.
2.2. Whole Exome Sequencing (WES) and Sanger Sequencing
WES and data analysis were performed as described previously [20]. Exome sequencing was conducted on two affected individuals and was enriched using the Nimblegen
SeqCap EZ Exome v2.0 Library (Roche Diagnostics; San Francisco, CA, USA). Segregation analysis of the FOXC1 variant was performed using Sanger sequencing on the DNA
samples of the seven participating family members.
2.3. In Vitro Localization Analysis
We subcloned human FOXC1, a single-coding exon gene, from genomic DNA samples,
into tdTomato-C1 vector and mutant FOXC1 into GFP-C2 (Clonetech) with Bgl II and Sal
I sites using infusion technology. Constructs were validated using Sanger sequencing.
Seventy percent confluent COS-7 cells were transfected using lipofectamine 2000. The
medium was replaced with 2% FBS-DMEM and then 24 h later it was replaced with
4% FBS-DMEM. After another 24 h cells were fixed with 4% PFA for 15 min at room
temperature, stained with DAPI to visualize nuclei and Phalloidin-647 to visualize the actin
cytoarchitecture in PBS with 0.1% triton-X to permeabilize the cells, washed 3 times with
PBS, and mounted on slides. The cells were imaged using a Zeiss 710 confocal microscope
with 0.5 µm step size and processed using ImageJ as detailed previously [21].
2.4. Meta-Analysis
A literature review of intrafamilial variability in FOXC1-related disorders due to
truncating variants was performed using The Human Gene Mutation Database (http:
//www.hgmd.cf.ac.uk/ac/index.php; last accessed on 18 January 2022). Initially, a comprehensive review of 134 publicly available reports of FOXC1-related disorder variants was
performed to identify those with truncating variants (n = 41). Further narrowing was performed to yield a final meta-analysis that reported detailed phenotypes of multiple affected
family members. These final variants were comprehensively compiled and analyzed.
3. Results
3.1. Patient Characteristics
The proband was a 38-year-old Caucasian female who presented with congenital
glaucoma, bilateral iris hypoplasia, and hypothyroidism. She is part of the fourth generation
of a five-generation family with a history of vision impairment along with multi-organ
disorder. There were 12 affected individuals documented across five generations in this
family, with glaucoma being the most predominant segregating phenotype. Out of the
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affected family members, seven were male and five were female. Numbered individuals
(Figure 1a) in the family, across a range of ages (21–68 years), received a dilated eye exam
as part of a comprehensive evaluation of visual function, and, based on clinical history,
evaluation of cardiac and renal function.

Figure 1. (a) Numbered individuals received a dilated eye examination. The predominant phenotype was congenital glaucoma, while other ocular and nonocular abnormalities exhibited variable
expression; (b) slit lamp analysis revealed multiple eye problems. The proband (IV-1) is a 38-year-old
female with congenital glaucoma, bilateral iris hypoplasia, and hypothyroidism. Family history is
consistent with a highly variable autosomal dominant condition that includes isolated glaucoma
(III-01), iris hypoplasia (IV-01), aniridia (V-02), cataract, hypothyroidism, and congenital heart anomalies; (c) representative Sanger sequencing chromatograms of FOXC1 exon from a normal (V-1) and
an affected (V-2) individuals of family LNG5, showing the c.313_314insA allele. All individuals
included within the LNG5 pedigree were tested with Sanger sequencing to confirm segregation and
full phenotypic penetrance; (d) schematic representation of FOXC1 gene and protein structure. Two
nuclear localization signals (NLS1 and NLS2) are present at both ends of the DNA-binding forkhead
box domain (FH). FOXC1 c.313_314insA [p.(Tyr105*)] disrupts the α-helical region of the FH domain
and removes NLS2 along with the carboxy tail. H—Helix. B—β-sheets. W—Winged helix.
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3.2. Clinical Examination
Clinical data and blood samples for DNA extraction were obtained from seven family
members with consent and made available for this study. The family history is consistent
with an autosomal dominant inheritance pattern presenting with highly variable symptoms
including isolated glaucoma (12 out of the 25 family members), iris hypoplasia, aniridia,
cataract, hypothyroidism, and congenital heart anomalies including mitral valve prolapse.
(Figure 1a,b). Other individuals, such as the proband and the proband’s mother (IV-1 and
III-1, respectively), had a variety of phenotypes: ranging from cardiac valvular disease to
iris hypoplasia to glaucoma.
3.3. Genetic Analysis
Whole exome sequencing was performed on two individuals, revealing a novel insertion variant (c.313_314insA) in FOXC1 (Figure 1c). This variant was predicted to lead to
early protein truncation [p.(Tyr105*)] (Figure 1c,d). Additionally, the variant is predicted to
disrupt the α-helical region of the DNA-binding forkhead box domain. Segregation of the
variant along with disease phenotype was then found in four additional family members
(Figure 1b) and was absent from an unaffected family member (Figure 1c). The allele
frequency of the truncating variant (c.313_314insA) was zero among the 126,000+ exomes
reported in the gnomAD database. The highly variable phenotypes found in the assessed
family spanned the entire spectrum of FOXC1-associated diseases and ranged from congenital glaucoma to Axenfeld-Rieger Syndrome (ARS). Axenfeld-Rieger Syndrome type 3 is an
autosomal dominant condition primarily characterized by developmental abnormalities
of the anterior segment and is also associated with systemic abnormalities such as cardiac
defects and hearing loss (OMIM ID: 602482). Our plausible explanation of the observed
variability of the phenotype, especially aniridia, observed in our family as compared to
other known FOXC1 alleles, might be the co-inheritance of a pathogenic variant of other
ASD-associated genes along with the c.313_314insA allele. However, through exome analysis, we found no pathogenic variants in other ASD-associated genes, which likely excludes
this possibility.
Next, to assess the functional impact of the novel FOXC1 variant, we generated
fluorescently tagged constructs, tdTomato-FOXC1WT , and GFP-FOXC1p.Tyr105* . Transient
transfection in COS-7 cells showed that FOXC1WT localized exclusively in the nucleus as
expected. The p.Tyr105* is positioned in between two known nuclear localization sequences,
NLS1 and NLS2. Hence, the variant-mediated early truncation was predicted to eliminate
NLS2. Corresponding to the in silico prediction, overexpression of FOXC1Tyr105* in COS-7
cells revealed that the variant protein was partially localized in the cytoplasm (Figure 2),
as opposed to the exclusive nuclear localization of WT protein. The mislocalization of the
FOXC1Tyr105* protein may likely disrupt its downstream transcriptional function. Overall,
our in vitro studies further support previous research that shows that both NLS1 and NLS2
motifs are essential for FOXC1 nuclear localization and without them, FOXC1 protein
localizes improperly to cytoplasmic regions [22].
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Figure 2. Representative images of COS-7 cells transiently transfected with tomato-tagged wild-type
(WT) or FOXC1 constructs. As compared to WT-FOXC1, which is primarily localized in the nucleus,
the truncated FOXC1 was also found in the cytoplasm. Scale bar—10 µm.

3.4. Literature Meta-Analysis
To further explore FOXC1-related intrafamilial variability, we performed a comprehensive literature review of early truncation alleles of FOXC1 that segregated in multiple
affected family members with available reported clinical phenotypes (Table 1; n = 12
publication, 56 affected individuals). A majority of the segregating variants were found
across multiple generations (11/12). Similar to our study, we found extensive variability
among intrafamilial phenotypes due to truncating variants (Table 1). All of the families
had individuals who could be categorized as “more severe” due to increased severity and
breadth of disease presentation, and individuals that could be categorized as “less severe”
due to the isolated presentation of phenotypes. The variation in the range of intrafamilial
disease severity is a general phenomenon among genetically inherited diseases, particularly
prominent in ocular and systemic diseases. Overall, only one family had affected individuals with only nonsyndromic presentations (normal systemic features), five families with
affected individuals who all had syndromic presentations, and six families with affected
individuals that had either syndromic, and nonsyndromic presentations. This supports the
fact that ASD cannot be ruled out in cases with nonsyndromic presentations and further
clinical evaluation is recommended.
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Table 1. Compilation of the genetic and phenotypic information related to truncating variants
associated with FOXC1 segregating within multiple family members.
DNA Change

Amino Acid
Change

Classification

Proband Phenotype

Intrafamilial Phenotypes

Reference

c.15delC

p.(Arg4Hisfs*43)

Frameshift

Congenital glaucoma,
optic atrophy

2 member, 2 generations;
optic atrophy, unilateral
superior oblique palsy

[23]

Nonsense

Posterior embryotoxon,
iris hypoplasia, ocular
hypertelorism, flat
midface, microdontia,
protuberant umbilical
skin

9 members, 3 generations;
posterior embryotoxon, iris
hypoplasia, glaucoma, flat
midface, microdontia,
ocular hypertelorism,
protuberant umbilical skin,
hearing loss, cardiac defect

[24]

Frameshift

Glaucoma, iridocorneal
adhesion, iris atrophy,
Haab’s striae, iris
hypoplasia, ocular
hypertelorism,
telecanthus, flat face, flat
broad nasal bridge

4 members, 2 generations;
corectopia, posterior
embryotoxon, elevated IOP,
glaucoma, iridocorneal
adhesion, iris hypoplasia,
iris atrophy, flat midface,
flat broad nasal bridge,
normal intelligence

[25]

Congenital glaucoma,
bilateral iris hypoplasia,
hypothyroidism

12 members, 5 generations;
glaucoma, iris hypoplasia,
aniridia, cataract,
hypothyroidism, congenital
heart anomalies (mitral
valve prolapse)

Present
Study

Nonsense

Displaced Schwalbe line,
iridocorneal adhesion,
iris hypoplasia,
glaucoma, leukoma,
maxillary hypoplasia,
ureteral stenosis

7 members, 3 generations;
posterior embryotoxon,
iridocorneal adhesion, iris
hypoplasia, corectopia,
glaucoma, maxillary
hypoplasia, ocular
hypertelorism, atrial septal
defect, ureteral stenosis,
protuberant umbilical skin

[26]

Nonsense

Corneal haze, elevated
IOP with normal cup to
disc ratio

4 members (3 affected, 1
unaffected with variant), 3
generations; secondary
glaucoma, phthisis bulbi,
total cupping

[14]

Frameshift

Glaucoma, posterior
embryotoxon, iris
hypoplasia, early-onset
glaucoma, hearing loss,
ocular hypertelorism,
telecanthus,
megalocornea

2 members, 2 generations;
posterior embryotoxon, iris
hypoplasia, corectopia,
early-onset severe glaucoma,
atrial septal defect, aortic
stenosis, pulmonary
stenosis, hearing loss, ocular
hypertelorism, telecanthus

[27]

c.67C>T

c.317delA

c.313_314insA

c.358C>T

c.367C>T

c.437_453del17

p.(Gln23*)

p.(Gln106Argfs*75)

p.(Tyr105*)

p.(Gln120*)

p.(Gln123*)

p.(Pro146Alafs*85)

Frameshift
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Table 1. Cont.
DNA Change

c.456G>A

c.477C>G

c.609delC

c.1193_1196
dupGCAA

c.1265C>A

Amino Acid
Change

p.(Trp152*)

p.(Tyr159*)

p.(Ala204Argfs*111)

p.(Met400Serfs*129)

p.(Ser422*)

Classification

Proband Phenotype

Intrafamilial Phenotypes

Reference

Nonsense

Childhood-onset
glaucoma with normal
IOP and visual acuity,
posterior embryotoxon,
peripheral iridocorneal
adherences, iris
hypoplasia, short
stature, maxillary
hypoplasia, dental
abnormalities

6 members, 3 generations;
developmental glaucoma,
posterior embryotoxon,
peripheral iridocorneal
adhesion, iris hypoplasia,
short stature, maxillary
hypoplasia, dental
abnormalities,

[6]

Nonsense

Abnormal eye
development
(unspecified),
leukoencephalopathy,
global developmental
delay, hyperreflexia

3 members, 2 generations;
abnormal eye development
(unspecified),
leukoencephalopathy

[28]

Frameshift

Corneal vascularization,
thickened cornea
(bilateral corneal opacity
with peripheral corneal
vascularization), corneal
perforation, iris
hypoplasia, posterior
embryotoxon, iris
heterochromia, whole
globe abnormalities
(unspecified), lens
extrusion, persistent
hyperplastic primary
vitreous, retinal
detachment, anterior
segment developmental
abnormalities, elevated
IOP, mostly absent
Bowman layer, absent
Descemet membrane,
absent endothelium,
central corneal cyst

3 members, 2 generations;
iris hypoplasia, posterior
embryotoxon, iris
heterochromia, peripheral
iridocorneal adhesions,
down-slanting palpebral
fissures, ocular
hypertelorism, malar
hypoplasia, mild
retrognathia, unusual
dentition

[29]

Frameshift

Congenital glaucoma,
microphthalmia, iris
anomalies, pupil
anomalies, dysmorphic
facial features, bilateral
club foot, mild cognitive
impairment, congenital
deafness

2 members, 2 generations;
non-congenital glaucoma,
hearing loss, club foot

[30]

Nonsense

Posterior embryotoxon,
corectopia,
megalocornea, ocular
hypertension, normal
systemic features

2 members, 1 generation;
glaucoma, no other ocular
features, normal systemic
features

[31]

# Note: All nonsense truncating alleles have zero minor allele frequency in the gnomAD database. 566 total amino
acids in FOXC1. IOP (intraocular pressure); fs—frameshift.
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While Axenfeld-Rieger anomaly was listed as a key clinical diagnosis for 9 out of 12
of the FOXC1 variants that are listed in Table 1, it does not capture the range of ocular
phenotypes that were observed in these families. Sixty-three percent of affected individuals
from Table 1 were affected with glaucoma and 61% were affected with ASD (Figure 3). Additionally, the range of ocular phenotypes include optic atrophy, Haab striae, iridocorneal
adhesion, iris atrophy, corectopia, posterior embryotoxon, elevated intraocular pressure,
aniridia, displaced Schwalbe line, corneal haze, phthisis bulbi, thickened cornea, iris heterochromia, corneal perforation, lens extrusion, retinal detachment, hyperplastic primary
vitreous, abnormalities of the Bowman layer, abnormalities of the Descemet membrane,
abnormalities of the corneal endothelium, corneal cysts, and megalocornea.

Figure 3. Prevalence of the commonly occurring clinical features among 56 individuals from 12 families affected with truncating variants of FOXC1 from Table 1 (n = 56 individuals).

Further, differences in the frequency of FOXC1-associated phenotypes were noted.
While relatively commonly occurring phenotypes are depicted in Figure 3, a significant
number of features were not common and some features were only unique to singular
families. Surprisingly, aniridia was not reported to be associated with FOXC1 in any of
the reviewed publications and to the best of our knowledge is a unique feature of the SNP
associated with the FOXC1-affected family reported in this study. Moreover, common
systemic abnormalities such as hearing impairment and cardiac-related abnormalities were
less common, only seen in 10% and 7% of the studied affected individuals found in the
meta-analysis, respectively.
4. Discussion
Here, we performed a genetic analysis on seven individuals from a large (12 of
25 family members were affected), multigenerational family, and we found a novel nonsense variant in FOXC1 causing extensive variable phenotypic expressivity among family
members, including variable iris hypoplasia and aniridia. Aniridia is a very uncommon
FOXC1-related phenotype. We observed intrafamilial clinical heterogeneity, the proband’s
sister (IV-2) presented with severe syndromic presentation including glaucoma, iris hypoplasia, cataract, and cardiac valvular disease, while other family members with the
same variant had milder phenotypic presentations. IV-1 (proband) only presented with iris
hypoplasia and glaucoma.
Meta-analysis of early truncation alleles of FOXC1-associated phenotypes revealed
extensive intrafamilial and interfamilial heterogeneity of ocular and systemic phenotypes
in 12 families. Variants in the PAX6 gene account for >90% of all aniridia cases, regardless
of whether they are familial (~66%) or sporadic (~33%) [32]. Previously, only one variant in
FOXC1 (c.454T>G; p.Trp152Gly) has been associated with aniridia [33]. We postulate that
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FOXC1-related aniridia appears to be the extreme end of iris hypoplasia rather than true
aplasia as is seen in PAX6-related aniridia [34]. However, due to logistical limitations, we
are not able to provide additional cellular validation to gain further insight into the real
relevance of the variant. Future studies may include such proposed assays.
Among the variants present in the final meta-analysis, one other variant shared
a common domain (helix 2) with the novel variant presented in this study. The family
associated with c.317delA suffered from a variety of ocular abnormalities such as corectopia
and iridocorneal adhesion and some of those phenotypes overlapped with those found
in our reported family: glaucoma and iris hypoplasia. In terms of systemic phenotypes,
our family was found to have abnormalities of the ocular, renal, and cardiac systems,
whereas the c.317delA-associated family’s systemic phenotypes only reportedly extended
to craniofacial abnormalities such as a flat broad nasal bridge or ocular hypertelorism [25].
In conclusion, the extent of similarities between the two families does not suggest a strong
correlation based upon the shared protein domain.
Additionally, there were six other pathogenic variants found to affect the same NLS signal (NLS2) as the novel variant found in this study [6,14,25–28]. Among these six families,
there was one family (c.367C>T-associated) that was reported to only have ocular phenotypes (non-systemic); however, this could be a limitation of clinical reporting. Besides this,
the rest of the families all reported systemic phenotypes in addition to ocular phenotypes.
The phenotypes affecting the other families ranged from atrial septal defect to short stature
to dental abnormalities. Glaucoma was present/reported in five out of the six families
and was the most commonly occurring phenotype among this subset [6,14,25–27]. Cardiac
anomalies were present in one other family in this subset besides ours [26]. Overall, there
was no clear correlation in phenotype among these six families that distinguished them from
the other families reported in Table 1. In previous research, a strong genotype–phenotype
correlation in FOXC1 has not been able to be elucidated either, but it has been suggested
that FOXC1 duplications and mutations that disrupt the inhibitory domain have increased
similarity in phenotype due to their similar mechanisms when compared to the phenotypes
associated with FOXC1 missense variants that are associated with haplodeficiency [35–37].
The phenomes from the meta-analysis present a variety of ocular abnormalities ranging
from Haab’s striae to cataract to microphthalmia with pronounced intrafamilial variability. In reference [31], the proband exhibited posterior embryotoxon, corectopia, megalocornea, and ocular hypertension but the affected sibling was only reported to have isolated
glaucoma. Additionally, one proband was affected with a range of ocular abnormalities:
glaucoma, microphthalmia, iris anomalies, and pupil anomalies, while the assessed parent
presented with only glaucoma [31]. Often, the phenotypic presentation of the proband
was the most severe among family members, which is not surprising since the proband
prompted the genetic investigation.
A review of the meta-analysis revealed additional variability among systemic features
related to FOXC1. While the predominant abnormalities were ocular, FOXC1-related
abnormalities also extended into other organ systems. Three families reported having
afflictions related to the cardiac system including the family reported in this study [24,27].
There were three families reported to have hearing impairments [24,27,30]. Interestingly,
protuberant umbilical skin, considered a salient feature for FOXC1-related ARS, was only
noted in two families. Global developmental delay was noted in only one family. However,
not all of these phenotypes have a causally established association with a FOXC1 variant.
While we cannot exclude the possibility that certain phenotypes are due to secondary
causes, such as a congenital malformation or a second Mendelian disease, the recurrent
observations of systemic findings in similar tissues systems warrants consideration of
systemic evaluations in all family members with FOXC1-related disorders.
The meta-analysis portion of our study further highlights the broad spectrum of
phenotypes associated with FOXC1, both in the variability of tissues affected and their
clinical co-morbidities. Surprisingly, the presentations that extended past ophthalmological
afflictions into other organ systems were less common than expected. This is possibly
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due to incomplete inclusion of all clinical details or differences in systemic investigations
performed in different reports across time, which is a limitation of a literature-based metaanalyses such as this. As such, the list of phenotypes described in Table 1 and Figure 3 may
be underrepresented. However, our findings do recommend comprehensive ocular and
systemic examinations, even when other family members are determined to have partial
phenotypic expression of FOXC1-related disorders.
Despite the extensive phenotypic variability observed in individuals harboring FOXC1
variants, the underlying mechanism of variability is currently unknown. Potential environmental factors/variability (e.g., drug exposure), reduced penetrance at the tissue level,
subclinical phenotypic features, and/or genetic modifiers may partially explain the clinical variability. Future studies with a larger sample size would be required to test these
rigorously.
In summary, our study further affirms the variability among individuals and families
with FOXC1-related ARS, as well as diagnostic and testing challenges. ASD should be
considered in apparently isolated congenital glaucoma or cataracts. The additional risk of
congenital cardiac and renal disease should also be taken into consideration where ASD
is noted. Therefore, the combination of systemic clinical and molecular analysis is likely
the most efficient approach to establish a diagnosis and complete a systemic evaluation
of ASD.
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